Jump to content



Recommended Posts

  • Root Admin

"Omiganan is a cationic antimicrobial peptide, a first-in-class for rosacea, that is entering into phase 3 trials. In a phase 2 dose-ranging study (N=240),[18] it showed a dose-dependent reduction in inflammatory lesions. The 2.5% formulation resulted in a 40% reduction at week 9. Cutaneous tolerability was good."  Hilary Baldwin, MD, What's New in Acne and Rosacea, Medscape Dermatology, April 29, 2016 [last paragraph of the article]  Omiganan (CLS001) developed by Cutanea

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Create New...

Important Information

Terms of Use